Skyrizi Surpasses Humira as AbbVie’s Top-Selling Drug

Revenue Shift:
Skyrizi has become AbbVie's top-selling drug, surpassing Humira for the first time with $3.2 billion in revenue.

Clinical Efficacy:
Skyrizi has been shown to be more effective than Humira in treating moderate-to-severe plaque psoriasis, with 72% of patients achieving 90% clearer skin at 16 weeks compared to 47% with Humira.

Market Impact:
Humira's revenue has declined significantly due to biosimilar competition, with a 35.9% decrease in global net revenues in the first quarter of 2024.

Strategic Importance:
Skyrizi is a key part of AbbVie's strategy to maintain its position in the immunology market, especially as Humira faces increasing competition from biosimilars.

Company Performance:
AbbVie remains the top pharma company in the immunology space, bolstered by its portfolio of "revolutionary" therapies, including Skyrizi and Humira.